Eli Lilly investiert 50 Millionen US-Dollar in Absci für KI-gestützte Haarausfall-Therapien
Pharmaceutical giant Eli Lilly and Company has moved to expand its footprint in generative biology by leading a $50 million investment round in Absci Corporation, a company specializing in artificial intelligence-driven drug discovery. The funding, which includes $40 million in equity, aims to accelerate the development of novel protein-based therapeutics, with early applications reportedly targeting … Read more